Lithium chloride induces mesenchymal-to-epithelial reverting transition in primary colon cancer cell cultures

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 1913-1923

  Costabile, Valeria ^a   Duraturo, Francesca ^a   Delrio, Paolo ^b   Rega, Daniela ^b   Pace, Ugo ^b   Liccardo, Raffaella ^a   Rosi, Giovanni Battista ^b   Genesio, Rita ^a   Nitsch, Lucio ^a   Izzo, Paola ^a,c   De Rosa, Marina ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Colorectal cancer; Epithelial to mesenchymal transition; GSK3 inhibition; Mesenchymal to epithelial transition; Primary colon cancer cell cultures; Stem cell like phenotype

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; CYTOKERATIN 18; CYTOKERATIN 20; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; LITHIUM CHLORIDE; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN; IMMUNOLOGICAL ADJUVANT; TUMOR MARKER; TUMOR PROTEIN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL DIFFERENTIATION; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CULTURE MEDIUM; CYTOGENETICS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYMAL EPITHELIAL TRANSITION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE; WESTERN BLOTTING; COLONIC NEOPLASMS; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; TUMOR CELL CULTURE; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CHROMOSOME ANALYSIS; IN VITRO STUDY; KARYOTYPING; PHENOTYPE; QUANTITATIVE ANALYSIS; STEM CELL;

ADJUVANTS, IMMUNOLOGIC; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL DIFFERENTIATION; COLONIC NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LITHIUM CHLORIDE; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84925424589     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2911     Document Type: Article

References (39)

1. Ewing I, Hurley JJ, Josephides E and Millar A: The molecular genetics of colorectal cancer. Frontline Gastroenterol 5: 26-30, 2014.
2. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
3. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
4. Yeung AT, Patel BB, Li XM, Seeholzer SH, Coudry RA, Cooper HS, Bellacosa A, Boman BM, Zhang T, Litwin S, Ross EA, Conrad P, Crowell JA, Kopelovich L and Knudson A: One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res 68: 7579-7586, 2008.
5. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW and Jones DA: A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 137: 623-634, 2009.
6. Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res 34: 2061-2068, 2014.
7. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479-507, 2011.
8. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
9. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko Z N, Cocco L, Martelli AM and Cervello M: GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5: 2881-2911, 2014.
10. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
11. Li H, Huang K, Liu X, Liu J, Lu X, Tao K, Wang G and Wang J: Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κB signaling pathway. Oxid Med Cell Longev 2014: 241864, 2014.
12. Mishra R: Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9: 144, 2010.
13. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, Dai H and Yeatman TJ: EMT is the dominant program in human colon cancer. BMC Med Genomics 4: 9, 2011.
14. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
15. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumor cells. Nat Cell Biol 2: 84-89, 2000.
16. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
17. Kreso A and O'Brien CA: Colon cancer stem cells. Curr Protoc Stem Cell Biol Chapter 3: Unit 3.1, 2008.
18. Liehr T, Weise A, Heller A, Starke H, Mrasek K, Kuechler A, Weier H U and Claussen U: Multicolor chromosome banding (MCB) with YAC/BAC-based probes and region-specific micro-dissection DNA libraries. Cytogenet Genome Res 97: 43-50, 2002.
19. Duraturo F, Cavallo A, Liccardo R, Cudia B, De Rosa M, Diana G and Izzo P: Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of a novel alu-mediated deletion. Biomed Res Int 2013: 219897, 2013.
20. Galatola M, Miele E, Strisciuglio C, Paparo L, Rega D, Delrio P, Duraturo F, Martinelli M, Rossi GB, Staiano A, Izzo P and De Rosa M: Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J Gastroenterol 19: 8659-8670, 2013.
21. Galatola M, Paparo L, Duraturo F, Turano M, Rossi GB, Izzo P and De Rosa M: Beta catenin and cytokine pathway dysregulation in patients with manifestations of the ?PTEN hamartoma tumor syndrome? BMC Med Genet 13: 28, 2012.
22. st edition. S. Karger AG, Basel, pp140, 2013.
23. Alberici P and Fodde R: The role of the APC tumor suppressor in chromosomal instability. Genome Dyn 1: 149-170, 2006.
24. Sameer AS, Nissar S and Fatima K: Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev 23: 246-257, 2014.
25. Therkildsen C, Jönsson G, Dominguez-Valentin M, Nissen A, Rambech E, Halvarsson B, Bernstein I, Borg K and Nilbert M: Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. Eur J Cancer 49: 1226-1235, 2013.
26. Castellví-Bel S, Castells A, Johnstone CN, Piñol V, Pellisé M, Elizalde JI, Romo N, Rustgi AK and Piqué JM: Evaluation of PARVG located on 22q13 as a candidate tumor suppressor gene for colorectal and breast cancer. Cancer Genet Cytogenet 144: 80-82, 2003.
27. Zheng HT, Peng ZH, Zhou CZ, Li DP, Wang ZW, Qiu GQ and He L: Detailed deletion mapping of loss of heterozygosity on 22q13 in sporadic colorectal cancer. World J Gastroenterol 11: 1668-1672, 2005.
28. Li X, Pei D and Zheng H: Transitions between epithelial and mesenchymal states during cell fate conversions. Protein Cell 5: 580-591, 2014.
29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial- mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
30. Jope RS: Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441-443, 2003.
31. Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjänen K, El-Faitori O, Latto M, Collan Y and Pyrhönen S: High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 33: 3137-3143, 2013.
32. Beurel E and Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189, 2006.
33. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
34. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, Kawakami K and Minamoto T: Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 98: 1388-1393, 2007.
35. Du Q and Geller DA: Cross-regulation between Wnt and NF-κB signaling pathways. For Immunopathol Dis Therap 1: 155-181, 2010.
36. Katoh M and Katoh M: Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades. Int J Mol Med 23: 763-769, 2009.
37. Conacci-Sorrell M, Zhurinsky J and Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109: 987-991, 2002.
38. Solanas G, Porta-de-la-Riva M, Agusti C, Casagolda D, Sánchez-Aguilera F, Larriba MJ, Pons F, Peiró S, Escrivà M, Muñoz A, Duñach M, de Herreros AG and Baulida J: E-cadherin controls beta-catenin and NF-kappaB transcriptional activity in mesenchymal gene expression. J Cell Sci 121: 2224-2234, 2008.
39. Benoit YD, Guezguez B, Boyd AL and Bhatia M: Molecular Pathways: Epigenetic modulation of wnt/glycogen synthase kinase-3 signaling to target human cancer stem cells. Clin Cancer Res 20: 5372-5378, 2014.